ERBB2 and neoplasm: CAR constructs targeting single tumour antigens have shown only occasional clinical improvements, but the field is now moving toward targeting multiple antigens with multivalent CARs, which is supported by a pre-clinical study where a trivalent CAR directed toward HER2, IL13Ra2, and EphA2 showed better cytotoxicity than that of monovalent CAR T cells [155].